PMID- 25375397
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20220408
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 17
IP  - 1
DP  - 2015 Jan
TI  - Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in 
      patients with type 2 diabetes: a systematic review and network meta-analysis.
PG  - 35-42
LID - 10.1089/dia.2014.0188 [doi]
AB  - INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new 
      class of drugs used in the treatment of type 2 diabetes mellitus (T2DM). 
      Gastrointestinal (GI) adverse events (AEs) are the most frequently reported 
      treatment-related AEs for GLP-1 RAs. We aim to evaluate the effect of GLP-1 RAs 
      on the incidence of GI AEs of T2DM. MATERIALS AND METHODS: The overview of the GI 
      events of GLP-1 RAs has been performed on relevant publications through the 
      literature search, such as MEDLINE, EMBASE, Cochrane Library, and 
      ClinicalTrials.gov The manufacturer was contacted regarding unpublished data. We 
      analyzed direct and indirect comparisons of different treatments using Bayesian 
      network meta-analysis. RESULTS: Taspoglutide 30 mg once weekly (TAS30QW) and 
      lixisenatide 30 mug twice daily (LIX30BID) were ranked the top two drugs in terms 
      of GI AEs versus placebo. The odds ratios of nausea and vomiting for TAS30QW were 
      11.8 (95% confidence interval [CI], 2.89, 46.9) and 51.7 (95% CI, 7.07, 415), 
      respectively, and that of diarrhea was 4.93 (95% CI, 1.75, 14.7) for LIX30BID. 
      CONCLUSIONS: Our study found all GLP-1 RA dose regimens significantly increased 
      the incidence of GI AEs, compared with placebo or conventional treatment. The 
      occurrence of GI AEs was different with diverse dose regimens of GLP-1 RAs. 
      TAS30QW had the maximum probability to occur nausea and vomiting, whereas 
      LIX30BID had the maximum probability to cause development of diarrhea versus 
      other treatments.
FAU - Sun, Feng
AU  - Sun F
AD  - 1 Department of Epidemiology and Biostatistics, School of Public Health, Peking 
      University Health Science Centre , Beijing, People's Republic of China .
FAU - Chai, Sanbao
AU  - Chai S
FAU - Yu, Kai
AU  - Yu K
FAU - Quan, Xiaochi
AU  - Quan X
FAU - Yang, Zhirong
AU  - Yang Z
FAU - Wu, Shanshan
AU  - Wu S
FAU - Zhang, Yuan
AU  - Zhang Y
FAU - Ji, Linong
AU  - Ji L
FAU - Wang, Jun
AU  - Wang J
FAU - Shi, Luwen
AU  - Shi L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Incretins)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Glucagon)
RN  - 2PHK27IP3B (taspoglutide)
RN  - 74O62BB01U (lixisenatide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diarrhea/chemically induced
MH  - Glucagon-Like Peptide 1/*adverse effects
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Incretins/*adverse effects
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Peptides/administration & dosage/adverse effects
MH  - Receptors, Glucagon/*agonists
MH  - Vomiting/chemically induced
PMC - PMC4290796
EDAT- 2014/11/07 06:00
MHDA- 2015/09/04 06:00
PMCR- 2016/01/01
CRDT- 2014/11/07 06:00
PHST- 2014/11/07 06:00 [entrez]
PHST- 2014/11/07 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.1089/dia.2014.0188 [pii]
AID - 10.1089/dia.2014.0188 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2015 Jan;17(1):35-42. doi: 10.1089/dia.2014.0188.